Insulet Announces Full Market Release of Omnipod® 5 Automated Insulin Delivery System in Germany
- Insulet expands market presence with the launch of Omnipod 5 in Germany
- Improved clinical outcomes demonstrated in the U.S.
- Integration with Dexcom G6 CGM system enhances functionality
- None.
“We know people in
Omnipod 5 is the first CE marked tubeless automated insulin delivery (also known as hybrid closed loop) system that integrates with the Dexcom G6 Continuous Glucose Monitoring (CGM) System. The system1 includes the tubeless Pod enhanced with SmartAdjust™ technology and a handheld Controller integrated with the SmartBolus Calculator. The system is interoperable with Dexcom G6 for automated insulin delivery to help protect against high and low glucose levels 2.
Laura Mysliwietz, a 29-year-old medical technologist, is beyond excited that Omnipod 5 is now available in her country. “Before I transitioned to Omnipod last year, I was using a traditional insulin pump, but the tubing was always in my way. Now, I sometimes forget that I have an insulin pump on my body,” said Laura. “Being tubeless makes my life so much easier, and the addition of an automated insulin delivery system will give me even more freedom to manage my type 1 diabetes. I can’t wait to use Omnipod 5!”
Insulet has presented real-world data from 36,634 adults3 and 18,516 children and adolescents4 with type 1 diabetes in the
Omnipod 5 is now available in
People with type 1 diabetes should contact their healthcare provider to get started with Omnipod 5. More information is also available on the Omnipod website.
The Company’s goal is to make Omnipod 5 available for the majority of Insulet’s European customers by the end of 2024.
1Integration with the Dexcom G6 CGM system is required for automated insulin delivery.
2Study in 240 people with T1D aged 6 to 70 years involving two weeks standard diabetes therapy followed by three months Omnipod 5 use in Automated Mode. Average time with high blood glucose in adults/adolescents and children, standard therapy vs. three-month Omnipod 5:
3Lal R., et al, 57-OR Presented at the American Diabetes Association Scientific Sessions 2023.
4Sherr J.L., et al, P-898 Presented at the American Diabetes Association Scientific Sessions 2023.
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD), headquartered in
Forward-Looking Statement:
This press release may contain forward-looking statements concerning Insulet's expectations, anticipations, intentions, beliefs, or strategies regarding the future. These forward-looking statements are based on its current expectations and beliefs concerning future developments and their potential effects on Insulet. There can be no assurance that future developments affecting Insulet will be those that it has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond its control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, and other risks and uncertainties described in its Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on February 24, 2023 in the section entitled "Risk Factors," and in its other filings from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of its assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Insulet undertakes no obligation to publicly update or revise any forward-looking statements.
©2023 Insulet Corporation. Omnipod, Omnipod 5, and SmartAdjust are trademarks or registered trademarks of Insulet Corporation in
Source: Insulet Corporation
View source version on businesswire.com: https://www.businesswire.com/news/home/20230828947492/en/
Investor Relations:
Deborah R. Gordon
Vice President, Investor Relations
(978) 600-7717
dgordon@insulet.com
Media:
Angela Geryak Wiczek
Senior Director, Corporate Communications
(978) 932-0611
awiczek@insulet.com
Source: Insulet Corporation